Display options
Cite
Gomaa AM, Galal HM, Abou-Elgait AT. Neuroprotective effects of melatonin administration against chronic immobilization stress in rats. Int J Physiol Pathophysiol Pharmacol. 2017;9(2):16-27
Gomaa, A. M., Galal, H. M., & Abou-Elgait, A. T. (2017). Neuroprotective effects of melatonin administration against chronic immobilization stress in rats. International journal of physiology, pathophysiology and pharmacology, 9(2), 16-27.
Gomaa, Asmaa Ms, et al. "Neuroprotective effects of melatonin administration against chronic immobilization stress in rats." International journal of physiology, pathophysiology and pharmacology vol. 9,2 (2017): 16-27.
Gomaa AM, Galal HM, Abou-Elgait AT. Neuroprotective effects of melatonin administration against chronic immobilization stress in rats. Int J Physiol Pathophysiol Pharmacol. 2017 Apr 15;9(2):16-27. eCollection 2017. PMID: 28533888; PMCID: PMC5435669.
Copy Download .nbib Format: NLM
Share it on

Int J Physiol Pathophysiol Pharmacol. 2017 Apr 15;9(2):16-27. eCollection 2017.

Neuroprotective effects of melatonin administration against chronic immobilization stress in rats.

International journal of physiology, pathophysiology and pharmacology

Asmaa Ms Gomaa, Heba M Galal, Amal T Abou-Elgait

Affiliations

  1. Department of Medical Physiology, Faculty of Medicine, Assiut UniversityAssiut, Egypt.
  2. Department of Histology, Faculty of Medicine, Assiut UniversityAssiut, Egypt.

PMID: 28533888 PMCID: PMC5435669

Abstract

Chronic stress can impair brain functions and play a well-known role in the development of stress-related disorders such as anxiety. Melatonin (Mel) is a neurohormone which regulate several physiological processes including mood and behavior. This experimental study was designed to evaluate the effect of Mel on chronic immobilization stress (CIS) for 6 weeks in rats and to elucidate its possible underlying mechanisms. Twenty-eight adult male Wistar albino rats were divided into four equal groups: the control group, the Mel-treated group which was injected daily with Mel (10 mg/kg/day; IP) for 6 weeks, the stressed group which was subjected to CIS protocol daily for 6 weeks, and the Mel-treated stressed group which was injected with Mel and concurrently exposed to CIS protocol for 6 weeks. The Mel-treated stressed group showed reduction of both relative adrenal weight and the serum corticosterone levels, suppression of the anxiety-like behavior, increased levels of serotonin, noradrenaline and oxytocin in the frontal cortex, and improved histopathological structure and decreased chromogranin A (CgA) protein expression in the frontal cortex when compared with the chronically stressed group. We concluded that Mel is anxiolytic and this effect was mediated in part by its ability to increase the central release of oxytocin and monoamines and to downregulate CgA protein expression in the frontal cortex.

Keywords: Chronic immobilization stress; melatonin; noradrenaline; oxytocin; serotonin

Conflict of interest statement

None.

References

  1. PLoS One. 2015 Nov 10;10(11):e0141898 - PubMed
  2. Neuron. 2012 Feb 9;73(3):553-66 - PubMed
  3. Sci Rep. 2015 Oct 01;5:14676 - PubMed
  4. Mol Psychiatry. 2015 Sep;20(9):1085-90 - PubMed
  5. Physiol Rev. 2007 Jul;87(3):873-904 - PubMed
  6. Indian J Med Res. 2012 Apr;135(4):548-54 - PubMed
  7. Int J Exp Pathol. 2015 Jun;96(3):196-202 - PubMed
  8. J Neuroendocrinol. 2004 Apr;16(4):308-12 - PubMed
  9. J Neurosci. 2015 Sep 2;35(35):12248-60 - PubMed
  10. J Clin Endocrinol Metab. 2003 Jan;88(1):450-8 - PubMed
  11. J Neurochem. 2006 Jun;97(5):1279-87 - PubMed
  12. Psychoneuroendocrinology. 2013 Sep;38(9):1883-94 - PubMed
  13. Neurosci Lett. 2013 Oct 25;555:137-42 - PubMed
  14. Brain Res. 1995 Dec 24;705(1-2):105-8 - PubMed
  15. Vet Pathol. 1989 Nov;26(6):488-98 - PubMed
  16. Mol Cell Endocrinol. 2016 Jan 15;420:169-79 - PubMed
  17. ISRN Urol. 2013 Nov 06;2013:278720 - PubMed
  18. J Pineal Res. 2008 May;44(4):341-7 - PubMed
  19. Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G946-53 - PubMed
  20. Psychoneuroendocrinology. 2014 Jul;45:31-42 - PubMed
  21. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):112-9 - PubMed
  22. Neurobiol Stress. 2015 Jan 1;1:116-127 - PubMed
  23. Pharmacol Res. 2003 Apr;47(4):349-54 - PubMed
  24. Psychopharmacology (Berl). 2014 Oct;231(21):4145-55 - PubMed
  25. Int J Legal Med. 2011 Jan;125(1):11-20 - PubMed
  26. Mitochondrion. 2016 Sep;30:168-76 - PubMed
  27. Neurochem Res. 2013 Oct;38(10):2227-36 - PubMed
  28. Neurochem Int. 1996 Dec;29(6):651-8 - PubMed
  29. Horm Behav. 2013 Mar;63(3):424-9 - PubMed
  30. Depress Anxiety. 2010 Apr;27(4):339-50 - PubMed
  31. Biomed Res. 2006 Feb;27(1):11-4 - PubMed
  32. Auton Neurosci. 2012 Apr 3;167(1-2):56-60 - PubMed
  33. Synapse. 1996 May;23(1):28-38 - PubMed
  34. Neuropsychopharmacology. 2015 Dec;40(13):2938-47 - PubMed
  35. Horm Behav. 2012 Nov;62(5):621-7 - PubMed
  36. J Indian Soc Periodontol. 2013 Mar;17(2):214-8 - PubMed
  37. Endocr Connect. 2014 Apr 29;3(2):R45-54 - PubMed
  38. Psychoneuroendocrinology. 2015 Feb;52:212-28 - PubMed
  39. Brain Res. 2014 Dec 17;1593:95-105 - PubMed

Publication Types